Patent ID: 11904001
Assignee: VIACYTE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A  C

Claim 0:
1. A method of reducing natural killer (NK) cell-mediated cell lysis of transplanted pancreatic endoderm cells (PEC) in a diabetic human, comprising:
transplanting a cell encapsulation device comprising PEC that are CHGA−, NKX6.1+, PDX1+ into a location in the diabetic human that permits host vascularization,
wherein the function of beta-2 microglobulin (B2M) and the function of Intercellular Adhesion Molecule 1 (ICAM1) are disrupted or inhibited in the PEC, resulting in a reduction of the NK-cell mediated cell lysis of the transplanted PEC in the diabetic human.